1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma
Year: 2024
Type: article
Source: Annals of Oncology
Authors: R. Dummer, R. Shapira, J. Pigozzo, P.A. Ascierto, C. Gaudy Marqueste, D. Portnoy, M. Del Vecchio, G. Bar-Sela, J.E. Cohen, A.M. Di Giacomo, A. Ribas, C. Dutriaux, C. Belli, G. Cohen, R. Dokhan, N. Jing, R. Lal, C. Krepler, G.V. Long
Institutions: University Hospital Zurich, Sheba Medical Center, Istituto Oncologico Veneto, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, West Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Emek Medical Center, Hadassah Medical Center, University of Siena, University of California, Los Angeles, Hôpital Saint-André, European Institute of Oncology, Life Groenkloof Hospital, Rambam Health Care Campus, Merck & Co., Inc., Rahway, NJ, USA (United States), MSD (UK) Limited (United Kingdom), The University of Sydney, Melanoma Institute Australia
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4402560985